The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in...
EQL has now taken the first step to establish itself in Germany and the Netherlands by recruiting key people with knowledge of the local markets who can identify, develop/in-license and launch nich...
EQL's key product Memprex[©] has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV, a leading local pharmaceutical company specialising in women’s h...
Annual Report 2024/25
Interim Report Q1
Annual General Meeting 2025
